Dear Shareholders, Exhibit 99.1 In Q1, Self-Serve delivered growth for the first time in three years, with a 6% year-over-year increase in quarterly bookings. We also expanded ARPU by 8% and achieved our highest dollar retention rate since Q3'21. Vimeo Enterprise experienced 32% revenue growth, 16% ARPU growth, and an 11% increase in customers. Product innovation accelerated with over 30 releases. Despite negative Free Cash Flow* due to bonus payouts and increased planned investments, we achieved our third ...

Financial Performance - Q1 2025 net revenue reached $283.6 million, a 6.9% increase year-over-year from $265.2 million in Q1 2024[4] - Adjusted EBITDA for Q1 2025 was $29.1 million, up from $25.9 million in Q1 2024, with an adjusted EBITDA margin of 10.3%[8] - Adjusted net income for Q1 2025 was $14.2 million, consistent with the prior year, resulting in adjusted diluted earnings per share of $0.67[7] - Net revenue for the three months ended March 31, 2025, was $283,578,000, an increase of $18,381,000 or 6.9% compared to $265,197,000 in 2024[27] - Total revenue for the same period was $287,442,000, reflecting a growth of $18,344,000 or 6.8% from $269,098,000 in 2024[27] - Net income for the three months ended March 31, 2025, was $13,306,000, a decrease of $726,000 or 5.2% from $14,032,000 in 2024[31] - Adjusted net income rose to $14,191,000, compared to $14,032,000 in 2024, indicating a stable performance despite the drop in net income[31] - Operating income for Q1 2025 was $16,228,000, slightly down from $16,274,000 in Q1 2024[37] Segment Performance - Executive Search segment net revenue increased by 5.9% to $213.4 million, driven by growth across all regions[9] - On-Demand Talent segment net revenue rose by 12.4% to $42.6 million, reflecting strong demand[10] - Heidrick Consulting segment net revenue grew by 6.8% to $27.6 million, indicating positive performance in consulting services[11] - Revenue breakdown for Q1 2025 included $213,390,000 from Executive Search, $42,564,000 from On-Demand Talent, and $27,624,000 from Heidrick Consulting[39] - Operating loss in the On-Demand Talent segment was $5,634,000 for Q1 2025, compared to a loss of $4,849,000 in Q1 2024[39] Expenses and Margins - Operating expenses increased to $271,214,000, up $18,390,000 or 7.3% from $252,824,000 in the previous year[27] - The company reported an operating margin of 5.7% for the three months ended March 31, 2025, compared to 6.1% in 2024[27] - Total adjustments to operating income in Q1 2025 amounted to $12,894,000, compared to $9,594,000 in Q1 2024[39] - Reorganization costs in Q1 2025 were $4,161,000, with no such costs reported in Q1 2024[37] Cash and Assets - Total current assets decreased to $595,150,000 from $772,977,000 as of December 31, 2024, a decline of $177,827,000[33] - Cash and cash equivalents at the end of the period were $211,944,000, down from $515,627,000 at the end of 2024, a decrease of $303,683,000[33] - Total liabilities decreased to $558,641,000 from $741,371,000, a reduction of $182,730,000[33] Future Outlook - The company expects Q2 2025 consolidated net revenue to be between $285 million and $305 million, influenced by macroeconomic factors[14] - Consultant productivity increased to $2.0 million per consultant, up from $1.9 million in the previous year[5] - Confirmations in Executive Search increased by 5.3%, contrasting with a 3.2% decline in the prior year[5] - The company continues to focus on market expansion and new product development as part of its strategic initiatives[39] Dividends - The Board of Directors declared a cash dividend of $0.15 per share, payable on May 29, 2025[13]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 6027 Edgewood Bend Court For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

Recent Business Highlights "We are very proud of our performance in the first quarter which included strong revenue growth and continued progress on profitability. We achieved a tremendous milestone with over 100,000 patients receiving Inspire therapy and we are still just getting started in growing awareness and adoption," said Tim Herbert, Chairman and CEO of Inspire Medical Systems. "We are now ready to launch of the Inspire V system and look forward to initiating the full launch this month in the U.S." ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ FORM 10-Q _______________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. COMMISSION FILE NO. 1-38012 Playa Hotels & Resorts N.V. (Exact name of registrant as specified in its c ...

Sales Performance - INGREZZA (valbenazine) first-quarter 2025 net product sales reached $545 million, an 8% increase compared to the first quarter of 2024[5] - CRENESSITY (crinecerfont) first-quarter 2025 net product sales were $14.5 million, with 413 total patient enrollment start forms indicating strong initial demand[5] - The company reaffirms 2025 net product sales guidance for INGREZZA in the range of $2.5 billion to $2.6 billion[2] - Total revenues for the first quarter of 2025 were $572.6 million, compared to $515.3 million in the first quarter of 2024[6] - Total revenues for the three months ended March 31, 2025, were $572.6 million, a 11.1% increase from $515.3 million in the same period of 2024[18] - Net product sales increased to $563.7 million, up 10.7% from $509.0 million year-over-year[18] Income and Earnings - GAAP net income for the first quarter of 2025 was $7.9 million, down from $43 million in the same period of 2024[9] - Non-GAAP net income for the first quarter of 2025 was $71.5 million, compared to $124.8 million in the first quarter of 2024[9] - Operating income decreased to $23.6 million, down 76.2% from $99.3 million in the same quarter of 2024[18] - Net income for the quarter was $7.9 million, a decline of 81.8% from $43.4 million in the previous year[18] - Non-GAAP net income was reported at $71.5 million, down 42.7% from $124.8 million in the same quarter of 2024[22] - Diluted earnings per share (EPS) on a GAAP basis was $0.08, compared to $0.42 in the prior year, reflecting an 81.0% decrease[22] Research and Development - The company initiated Phase 3 registrational programs for osavampator in major depressive disorder and NBI-'568 in schizophrenia[7] - Research and development expenses rose significantly to $263.2 million, a 65.1% increase compared to $159.4 million in the prior year[18] - The company plans to invest $960 million to $1.010 billion in GAAP R&D expenses for the full year 2025[10] Financial Position - The company has approximately $1.8 billion in cash, cash equivalents, and marketable securities as of March 31, 2025[9] - Cash, cash equivalents, and marketable securities totaled $943.5 million as of March 31, 2025, down from $1,076.1 million at the end of 2024[20] - Total assets decreased to $3,687.7 million from $3,718.7 million at the end of 2024[20] - Stockholders' equity declined to $2,535.7 million, down from $2,589.7 million at the end of the previous year[20] Share Repurchase - A second share repurchase program was announced to repurchase up to $500 million of outstanding common stock, with $150 million already repurchased as of March 31, 2025[9]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14585 FIRST HAWAIIAN, INC. (Exact Name of Registrant as Specified in its Charter) Not Applicable (Former name, former add ...

Financial Performance - Syndax reported $20.0 million in net revenue from Revuforj in the first quarter of 2025, marking the first full quarter of its U.S. launch[5] - Niktimvo generated $13.6 million in net revenue in its first partial quarter of launch, with Syndax recording a $0.2 million share of the net commercial loss[10] - Product revenue for the first quarter of 2025 was $20,042,000, compared to $0 in the same period of 2024[34] - Net loss for Q1 2025 was $84,846,000, compared to a net loss of $72,400,000 in Q1 2024, indicating a 17.2% increase in losses[34] - Basic loss per share attributable to common stockholders was $0.98 in Q1 2025, compared to $0.85 in Q1 2024, reflecting a 15.3% increase[34] Expenses - Research and development expenses increased to $61.6 million in Q1 2025, up from $56.5 million in the same period last year, primarily due to axatilimab-related costs[12] - Selling, general and administrative expenses rose to $41.0 million in Q1 2025, compared to $23.0 million in the prior year, driven by increased employee-related expenses[13] - The company expects R&D expenses for Q2 2025 to be between $70 million and $75 million, with total expenses (R&D plus SG&A) projected at $110 million to $115 million[15] - Total operating expenses increased to $103,799,000 in Q1 2025, up from $79,514,000 in Q1 2024, representing a 30.5% increase[34] - Research and development expenses rose to $61,636,000 in Q1 2025, compared to $56,492,000 in Q1 2024, marking an increase of 9.5%[34] - Selling, general and administrative expenses increased significantly to $41,031,000 in Q1 2025 from $23,022,000 in Q1 2024, a rise of 78.3%[34] Cash and Assets - The company had cash, cash equivalents, and investments totaling $602.1 million as of March 31, 2025, expected to fund operations to profitability[9] - Cash, cash equivalents, and investments decreased to $602,135,000 as of March 31, 2025, down from $692,404,000 as of December 31, 2024, a decline of 13.0%[32] - Total assets decreased to $640,707,000 as of March 31, 2025, compared to $724,816,000 as of December 31, 2024, a reduction of 11.6%[32] - Total stockholders' equity fell to $215,059,000 as of March 31, 2025, down from $288,124,000 as of December 31, 2024, a decrease of 25.3%[32] - Common stock outstanding increased to 86,047,032 shares as of March 31, 2025, compared to 85,694,443 shares as of December 31, 2024[32] Product Development and Market Opportunities - Syndax plans to initiate multiple trials of revumenib in combination with standard care regimens for newly diagnosed acute leukemia patients starting in the second half of 2025[8] - The company submitted a supplemental New Drug Application (sNDA) for revumenib for the treatment of R/R mNPM1 AML in April 2025, seeking Priority Review[5] - Revuforj and Niktimvo are positioned to unlock multi-billion-dollar opportunities in their respective markets, supported by strong clinical data and ongoing trials[3]

Financial Performance - Revenues for Q1 2025 increased by 11.3% to $738.3 million compared to $663.3 million in Q1 2024[2] - Net income attributable to common stockholders rose 274.5% to $364.8 million, or $3.26 per diluted share, from $97.4 million, or $0.87 per diluted share, in the prior year[7] - Total revenues for Q1 2025 were $738.3 million, an increase of 11.3% compared to $663.3 million in Q1 2024[29] - Net income attributable to common stockholders for Q1 2025 was $364,751,000, compared to $97,441,000 in Q1 2024, representing a significant increase[35] - Earnings per share (EPS) for Q1 2025 were $3.27 (basic) and $3.26 (diluted), compared to $0.88 (basic) and $0.87 (diluted) in Q1 2024[29] - The pre-tax margin for Q1 2025 was 63.9%, significantly higher than 20.4% in Q1 2024[29] - Adjusted net income before income taxes for Q1 2025 was $169.5 million, compared to $146.3 million in Q1 2024[33] - The adjusted pre-tax margin for Q1 2025 was 23.0%, up from 22.1% in Q1 2024[33] - Adjusted diluted earnings per share before income taxes increased to $1.51 in Q1 2025 from $1.31 in Q1 2024, reflecting a growth of 15.3%[35] Revenue Sources - Rental revenues increased by approximately 5% to $645 million, driven by fleet growth, despite a $12.7 million decrease in end-of-lease revenue[5] - Aircraft sales and trading revenues surged by 90% to $93 million, with gains from the sale of 16 aircraft totaling $61 million[6] - The company recognized a net benefit of $332 million from insurance settlements related to aircraft detained in Russia[9] Assets and Liabilities - Total assets increased to $32.36 billion as of March 31, 2025, compared to $32.28 billion at the end of 2024[27] - Total liabilities decreased to $24.50 billion as of March 31, 2025, down from $24.75 billion at the end of 2024[27] - The company ended the quarter with $29.2 billion in committed minimum future rental payments, including $18.9 billion from the existing fleet[9] - The owned fleet consisted of 487 aircraft, with a net book value of $28.6 billion, and a weighted average fleet age of 4.7 years[10] - The company has approximately $741 million in its aircraft sales pipeline, including $552 million in flight equipment held for sale[9] Cash Flow and Dividends - Net cash provided by operating activities for Q1 2025 was $388,346,000, compared to $371,330,000 in Q1 2024, an increase of 4.6%[40] - Net cash used in investing activities was $102,200,000 in Q1 2025, significantly improved from $630,324,000 in Q1 2024[40] - Cash dividends paid on Class A common stock increased to $24,503,000 in Q1 2025 from $23,316,000 in Q1 2024[40] - A quarterly cash dividend of $0.22 per share was approved by the board of directors, to be paid on July 9, 2025[9] Cash Position - Cash and cash equivalents as of March 31, 2025, were $456.6 million, a decrease from $472.6 million at the end of 2024[27] - The company reported a net decrease in cash of $15,491,000 for Q1 2025, contrasting with a net increase of $91,433,000 in Q1 2024[40] - Cash, cash equivalents, and restricted cash at the end of Q1 2025 totaled $460,613,000, down from $555,925,000 at the end of Q1 2024[40] - The company incurred cash paid for income taxes of $38,000 in Q1 2025, a decrease from $3,033,000 in Q1 2024[40]